DP
Therapeutic Areas
Captura Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| C2E2 | Treatment of internal radioactive contamination (e.g., from nuclear accidents, radiological incidents) | Pre-clinical |
Leadership Team at Captura Biopharma
MB
Michael B. Geranen
CEO, Co-Founder
AS
Anthony Soscia
President, Co-Founder
DG
Dr. Gary Barnette, Ph.D.
Regulatory